Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 255
- Q4 2025, +84 vs. previous quarter
- 13F value
- $7.36B
- Reported value at the end of Q4 2025
- Superinvestors holding
- 3
- At the end of Q4 2025
Superinvestors holding CDTX, Q4 2025
3 superinvestors report holding Cidara Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Maverick Capital
Lee Ainslie
1.1%
Cidara Therapeutics, Inc.'s share of the portfolio
- Shares
- 455,978
- Value
- $100.7M
Soros Fund Management
George Soros
0.8%
Cidara Therapeutics, Inc.'s share of the portfolio
- Shares
- 275,000
- Value
- $60.7M
| Superinvestor | Weight | Value |
|---|---|---|
| Duquesne Family Office | 0.3% | $10.9M |
Latest insider trades
Open-market purchases and sales by Cidara Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2026 (view filing) | Mar 31, 2017-Nov 10, 2020 | 3,204 daysLate | Stein JeffreyPresident & CEO | PPurchase | +4.26K | $79.55 | +$339.1K | +6.5%69.4K after | 4 lots |
| Dec 12, 2025 (view filing) | Dec 10 | 2 days | Ward ShaneCOO & CLO | SSale | −9.96K | $220.08 | −$2.19M | −28.5%25.0K after | |
| Sep 15, 2025 (view filing) | Sep 11 | 4 days | Davarpanah Nicole NegarChief Medical Officer | SSale | −474 | $62.86 | −$29.8K | −1.5%31.4K after | |
| Jun 30, 2025 (view filing)4:56 PM ET | Jun 26 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | PPurchase | +2.27M | $44.00 | +$100.0M | +208.0%3.37M after | |
| Jun 4, 2025 (view filing) | Jun 2-3 | 2 days | Mineo ChrysaDirector | PPurchase | +3.32K | $22.26 | +$73.9K | New position3.32K after | 2 lots |
| Mar 13, 2025 (view filing) | Mar 11 | 2 days | Ward ShaneCOO & CLO | SSale | −1.66K | $21.96 | −$36.5K | −10.2%14.7K after | |
| Mar 13, 2025 (view filing) | Mar 11 | 2 days | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −1.77K | $21.96 | −$38.9K | −9.9%16.2K after | |
| Sep 13, 2024 (view filing) | Sep 11 | 2 days | Sandison TaylorChief Medical Officer | SSale | −924 | $11.64 | −$10.8K | −3.9%23.1K after | |
| Sep 13, 2024 (view filing) | Sep 11 | 2 days | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −909 | $11.64 | −$10.6K | −4.9%17.8K after | |
| Jun 11, 2024 (view filing) | Jun 7 | 4 days | Stein JeffreyPresident & CEO | PPurchase | +8.00K | $13.21 | +$105.7K | +48.3%24.6K after |
Top 10 13F holders, Q4 2025
The largest institutional positions in Cidara Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 3,365,523 | $743.4M | 7.62% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,007,193 | $443.4M | 0.01% | +776,527+63.1% | Added |
| BlackRock, Inc. | 1,680,662 | $371.2M | 0.01% | +515,209+44.2% | Added |
| HBK Investments L P | 1,260,000 | $278.3M | 3.01% | +1,260,000 | New |
| FIL Ltd | 1,257,574 | $277.8M | 0.21% | +1,257,574 | New |
| UBS Group AG | 1,074,924 | $237.4M | 0.05% | +601,370+127.0% | Added |
| Darwin Global Management, Ltd. | 997,196 | $220.2M | 4.46% | 00.0% | Unchanged |
| Vivo Capital, LLC | 956,670 | $211.3M | 13.66% | −354,755−27.1% | Reduced |
| State Street Corp | 884,374 | $195.3M | 0.01% | +111,615+14.4% | Added |
| Jefferies Financial Group Inc. | 766,520 | $169.3M | 1.39% | +401,520+110.0% | Added |